Trust Department MB Financial Bank N A reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.1% during the 4th quarter, Holdings Channel reports. The firm owned 67,531 shares of the biopharmaceutical company’s stock after selling 4,373 shares during the period. Trust Department MB Financial Bank N A’s holdings in Gilead Sciences were worth $4,838,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of the business. Welch Investments LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth $108,000. Wealthcare Advisory Partners LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth $133,000. Horan Capital Advisors LLC. acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth $144,000. Hanson & Doremus Investment Management lifted its stake in shares of Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth $147,000. 76.47% of the stock is currently owned by institutional investors.
Several analysts have recently commented on GILD shares. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price for the company. in a research note on Wednesday, January 17th. BMO Capital Markets reduced their target price on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. Credit Suisse Group reiterated a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research note on Thursday, December 7th. Maxim Group set a $94.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday, December 11th. Finally, Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $87.04.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $80.70 on Friday. The company has a current ratio of 3.55, a quick ratio of 3.48 and a debt-to-equity ratio of 1.10. The stock has a market cap of $105,415.91, a PE ratio of 23.19, a price-to-earnings-growth ratio of -1.85 and a beta of 1.22. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.70 earnings per share. equities analysts expect that Gilead Sciences, Inc. will post 6.24 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.83%. Gilead Sciences’s payout ratio is 59.77%.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2018/02/18/trust-department-mb-financial-bank-n-a-lowers-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.